Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms, Nerve Tissue 2Neoplasms 2Glioma 2Glioblastoma 2Brain Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 76Temozolomide 73Specimen Handling 49Radiotherapy 46Radiosurgery 34Cyclophosphamide 28Bevacizumab 26Radiation 25pembrolizumab 24Biopsy 23Nivolumab 21Carboplatin 16fludarabine 14X-Rays 13Ipilimumab 13Surgical Procedures, Operative 12Lomustine 12Irinotecan 12Vincristine 11Topotecan 11Cisplatin 11Blood Specimen Collection 11dinutuximab 10trametinib 9abemaciclib 9AZD 6244 9lutetium Lu 177 dotatate 8Immunoglobulin G 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
contrast agent BR1 × CNS × 90 days × Clear all
NCT06329570 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NaviFUS Corporation

Phase 1/2 Recruiting
10 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT06496971 2026-04-09

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

NaviFUS Corporation

Phase 3 Recruiting
32 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡